Strengthening study habits through information and communication technologies

El propósito de la investigación correspondió a fortalecer el hábito a través del mejoramiento de la lectoescritura a partir de las Tecnologías de Información y Comunicación como herramienta estratégica. Desde los procesos investigativo derivados de la integración de la Investigación como Estrategia Pedagógica. Metodológicamente la investigación es de tipo cuantitativo- descriptivo. La unidad de análisis estuvo constituida por 60 estudiantes pertenecientes a los grados tercero y quinto, entre las edades de 7 a 12 años. Los resultados derivados dan cuenta de los procesos de mejoramiento y fortalecimiento de los hábitos de estudio en los estudiantes involucrados en el proceso investigativo a través del uso de las TIC. A través del proceso investigativo se puede concluir que como estrategia de enseñanza aprendizaje es positivo la implementación de las TIC a fin de mejorar los resultados obtenidos por los estudiantes en las pruebas locales y nacionalesThe purpose of the research was to strengthen the habit through the improvement of literacy based on Information and Communication Technologies as a strategic tool. From the research processes derived from the integration of Research as a Pedagogical Strategy. Methodologically, the research is quantitative-descriptive. The analysis unit consisted of 60 students belonging to the third and fifth grades, between the ages of 7 to 12 years. The derived results show the processes of improvement and strengthening of study habits in students involved in the research process through the use of ICT. Through the research process it can be concluded that the implementation of ICTs is positive as a teaching-learning strategy in order to improve the results obtained by students in local and national test

Which patients benefit from adding short-term psychodynamic psychotherapy to antidepressants in the treatment of depression? A systematic review and meta-analysis of individual participant data

Background: Adding short-term psychodynamic psychotherapy (STPP) to antidepressants increases treatment efficacy, but it is unclear which patients benefit specifically. This study examined efficacy moderators of combined treatment (STPP + antidepressants) v. antidepressants for adults with depression. Methods: For this systematic review and meta-analysis (PROSPERO registration number: CRD42017056029), we searched PubMed, PsycINFO, Embase.com, and the Cochrane Library from inception to 1 January 2022. We included randomized clinical trials comparing combined treatment (antidepressants + individual outpatient STPP) v. antidepressants in the acute-phase treatment of depression in adults. Individual participant data were requested and analyzed combinedly using mixed-effects models (adding Cochrane risk of bias items as covariates) and an exploratory machine learning technique. The primary outcome was post-treatment depression symptom level. Results: Data were obtained for all seven trials identified (100%, n = 482, combined: n = 238, antidepressants: n = 244). Adding STPP to antidepressants was more efficacious for patients with high rather than low baseline depression levels [B = -0.49, 95% confidence interval (CI) -0.61 to -0.37, p 2 years rather than <1 year (B = -0.68, 95% CI -1.31 to -0.05, p = 0.03) and than 1-2 years (B = -0.86, 95% CI -1.66 to -0.06, p = 0.04). Heterogeneity was low. Effects were replicated in analyses controlling for risk of bias. Conclusions: To our knowledge, this is the first study that examines moderators across trials assessing the addition of STPP to antidepressants. These findings need validation but suggest that depression severity and episode duration are factors to consider when adding STPP to antidepressants and might contribute to personalizing treatment selection for depression

Efficacy and moderators of short-term psychodynamic psychotherapy for depression: A systematic review and meta-analysis of individual participant data

Background: Short-term psychodynamic psychotherapy (STPP) is frequently used to treat depression, but it is unclear which patients might benefit specifically. Individual participant data (IPD) meta-analyses can provide more precise effect estimates than conventional meta-analyses and identify patient-level moderators. This IPD meta-analysis examined the efficacy and moderators of STPP for depression compared to control conditions. Methods: PubMed, PsycInfo, Embase, and Cochrane Library were searched September 1st, 2022, to identify randomized trials comparing STPP to control conditions for adults with depression. IPD were requested and analyzed using mixed-effects models. Results: IPD were obtained from 11 of the 13 (84.6%) studies identified (n = 771/837, 92.1%; mean age = 40.8, SD = 13.3; 79.3% female). STPP resulted in significantly lower depressive symptom levels than control conditions at post-treatment (d = -0.62, 95%CI [-0.76, -0.47], p < .001). At post-treatment, STPP was more efficacious for participants with longer rather than shorter current depressive episode durations. Conclusions: These results support the evidence base of STPP for depression and indicate episode duration as an effect modifier. This moderator finding, however, is observational and requires prospective validation in future large-scale trials

12-month Follow-up Analysis Of A Multicenter, Randomized, Prospective Trial In De Novo Liver Transplantation Recipients (lis2t) Comparing Cyclosporine Microemulsion (c2 Monitoring) And Tacrolimus

The LIS2T study was an open-label, multicenter study in which recipients of a primary liver transplant were randomized to cyclosporine microemulsion (CsA-ME) (Neural) (n = 250) (monitoring of blood concentration at 2 hours postdose) C2 or tacrolimus (n = 245) (monitoring of trough drug blood level[predose])Co to compare efficacy and safety at 3 and 6 months and to evaluate patient status at 12 months. All patients received steroids with or without azathioprine. At 12 months, 85% of CsA-ME patients and 86% o tacrolimus patients survived with a functioning grat (P not significant). Efficacy was similar in deceased-and living-donor recipients. Significantly fewer hepatitis C-positive patients died or lost their graft by 12 months with CsA-ME 95/ 88,6%) than with tacrolimus (14/85,16%) (P&lt; 0.03). Recurrence of hepatitis C virus in liver grafts was similar in each group. Based on biopsies driven by clinical events, the mean time to histological diagnosis of hepatitis C virus recurrence was significantly longer with CsA-ME (100 ± 50 days) than with tacrolimus (70 ± 40 days) (P &lt; 0.05). Median serum creatinine at 12 months was 106 μmol/L with CsA-ME and with tacrolimus. More patients who were nondiabetic at baseline received antihyperglycemic therapy in the tacrolimus group at 12 months was (13% vs. 5%, P&lt; 0.01). Of patients who were diabetic at baseline, more tacrolimus-treated individuals required anti-diabetic treatment at 12 months ( 70% vs. 49%, P+ 0.02). Treatment for de novo or preexisting hypertension or hyperlipidemia was similar in both groups. In conclusion, the efficacy of CsA-ME monitored by blood concentration at 2 hours postdose and tacrolimus in liver transplant patients is equivalent to 12 months, and renal function is similar. More patients required antidiabetic therapy with tacrolimus regardless of diabetic status at baseline. © 2006 AASLD.121014641472United Network for Organ Sharing Data Report: Liver Kaplan-Meier Graft Survival Rates for Transplants Performed 1996-2001 (2004), http://www.optn.org, Available at: Accessed: February 2Vogt, D.P., Henderson, J.M., Carey, W.D., Barnes, D., The long-term survival and causes of death in patients who survive at least 1 year after liver transplantation (2002) Surgery, 132, pp. 775-780Johnston, S.D., Morris, J.K., Cramb, R., Gunson, B.K., Neuberger, J., Cardiovascular morbidity and mortality after orthotopic liver transplantation (2002) Transplantation, 73, pp. 901-906Neal, D.A., Tom, B.D., Luan, J., Wareham, N.J., Gimson, A.E., Delrivere, L.D., Is there disparity between risk and incidence of cardiovascular disease after liver transplant? (2004) Transplantation, 77, pp. 93-99O'Grady, J.G., Burroughs, Hardy, P., Elbourne, D., Truesdale, A., Tacrolimus versus microemulsified ciclosporin in liver transplantation: The TMC randomised controlled trial (2002) Lancet, 360, pp. 1119-1125Mühlbacher, F., Tacrolimus versus cyclosporin microemulsion in liver transplantation: Results of a 3-month study (2001) Transplant Proc, 33, pp. 1339-1340. , European Liver Transplantation Tacrolimus vs Cyclosporin Microemulsion Study GroupLevy, G., Villamil, F., Samuel, D., Sanjuan, F., Grazi, G.L., Wu, Y., Results of LIS2T, a multicenter, randomized study comparing cyclosporine microemulsion with C2 monitoring and tacrolimus with Co monitoring in de novo liver transplantation (2004) Transplantation, 77, pp. 1632-1638Levy, G., Burra, P., Cavallari, A., Duvoux, C., Lake, J., Mayer, A.D., Improved clinical outcomes for liver transplant recipients using cyclosporine monitoring based on 2-hr post-dose levels (C2) (2002) Transplantation, 73, pp. 953-959Villamil, F., Pollard, S., C2 monitoring of cyclosporine in de novo liver transplant recipients: The clinician's perspective (2004) Liver Transpl, 10, pp. 577-583Yantorno, S.E., Varela, E.B., Raffa, S.R., Descalzi, V.I., Gomez Carretero, M.L., Pirola, D.A., How common is delayed cyclosporine absorption following liver transplantation? (2005) Liver TranspI, 11, pp. 167-173Watashi, K., Hijakata, M., Hosaka, M., Yamaji, M., Shimotohno, K., Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes (2003) Hepatology, 38, pp. 1282-1288Nakagawa, M., Sakamoto, N., Enomoto, N., Tanabe, Y., Kanazawa, N., Koyama, T., Specific inhibition of hepatitis C virus replication by cyclosporin A (2004) Biochem Biophys Res Commun, 313, pp. 42-47Manir̀e, T., Ethier, C., Raymond, V.A., Andre, A., Bilodeau, M., Evaluation of the effect of immunosuppressive agents on hepatitis C: Cyclosporine reduces viral replication in the replicon model (2004) Transplantation, 78 (SUPPL. 1), pp. 13-14. , [abstract]Sheiner, P.A., Schwartz, M.E., Mor, E., Schulager, L.K., Theise, N., Kishikawa, K., Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation (1995) Hepatology, 21, pp. 30-34Johnson, M.W., Washburn, W.K., Freeman, R.B., Fitzmaurice, S.E., Dienstag, J., Basgoz, N., Hepatitis C viral infection in liver transplantation (1996) Arch Surg, 131, pp. 284-291Paik, S.W., Tan, H.P., Klein, A.S., Boitnott, J.K., Thulavath, P.J., Outcome of orthotopic liver transplantation in patients with hepatitis C (2002) Dig Dis Sci, 47, pp. 450-455Duvoux, C., Mennecier, D., Pageaux, G., Conti, F., Roudot-Thoraval, F., Dhumeaux, D., Immunosuppression with tacrolimus an absence of antihypertensive therapy are associated with fibrosis progression after hepatitis C virus (HCV) graft reinfection (2002) Transplantation, 74 (SUPPL.). , International Society of Transplantation Congress 2002 [abstract 2652]Hunt, J., Gordon, F.D., Lewis, W.D., Histological recurrence and progression of hepatitis C after orthotopic liver transplantation: Influence of immunosuppressive regimens (2001) Liver Transpl, 7, pp. 1056-1063Berenguer, M., Prieto, M., San Juan, F., Rayon, J.M., Martinez, F., Carrasco, D., Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients (2002) Hepatology, 36, pp. 202-210Ghobrial, R.M., Farmer, D.G., Baquerizo, A., Orthotopic liver transplantation for hepatitis C: Outcome, effect of immunosuppression, and causes of retransplantation duringan 8-year single-center experience (1999) Ann Surg, 6, pp. 824-833Neumann, U.P., Berg, T., Bahra, M., Puhl, G., Guckelberger, O., Langrehr, J.M., Long-term outcome of liver transplants for chronic hepatitis C: A 10-year follow-up (2004) Transplantation, 77, pp. 226-231Ericzon, B., Groth, C., Bismuth, H., Calne, R., McMaster, P., Neuhaus, P., Glucose metabolism in liver transplant recipients treated with FK 506 or cyclosporin in the European multicentre study (1994) Transplant Int, 7 (SUPPL.), pp. Sll-S14Lohmann, T., List, C., Lamesch, P., Kohlhaw, K., Wenzke, M., Schwarz, C., Diabetes mellitus and islet cell specific autoimmunity as adverse effects of immunosuppressive therapy by FK506/tacrolimus (2000) Exp Clin Endocrinol Diabetes, 108, pp. 347-352Prasad, G.V., Kim, S.J., Huang, M., Kohlhaw, K., Zaltzman, J.S., Fenton, S.S., Reduced incidence of new-onset diabetes mellitus after renal transplantation with 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors (statins) (2004) Am J Transplant, 4, pp. 1897-190